The success rate for launching new active substances from Phase I studies remains critically low (<10%) for the period 2010 - 2017.^[1] Among therapeutic areas, nervous system disorders belong to those with the lowest probability of success, largely due to the limited predictive power of current preclinical models. The complexity of the blood brain barrier and the intricacies of chronic neurological disorders further hinder the ability to replicate disease conditions in vitro. Additionally, effective drug delivery across the blood-brain barrier remains a major obstacle in developing new treatments. This session will explore how emerging technologies—such as organoids, targeted drug delivery via microspheres, imaging, and artificial intelligence—advance translational brain research. Emphasis will be put on improving the translation of preclinical findings to clinical applications. These technologies hold the potential to contribute, in combination with other technologies, to accelerate CNS drug development and improve therapeutic success rates.